<< New survey illustrates confused state of people about how they will pay for long-term care services | Focus on healthy lifestyle to maintain weight this holiday season >>

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Published on November 13, 2009 at 5:32 AM · No Comments

Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA.

A material clinical update relating to both the PCI-24781 (HDAC Inhibitor) and PCI-32765 (BTK Inhibitor) programs will be presented at 6pm-8pm EST on Sunday, December 6, 2009 and Monday, December 7, 2009, respectively. The Company plans to issue a press release and hold a conference call related to the above items on December 8, 2009.

Poster details are as follows:

Title: Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma

Continued on Next page >>

HSP40/70 linked to hepatitis C infectionResearchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide...
GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UCJanssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestin...
Texas Children's Hospital and Baylor College of Medicine create Texas Children's Center for Global HealthTexas Children's Hospital and Baylor College of Medicine (BCM) today announced the creation of the T...
Novavax reports positive results from Phase II study of trivalent VLP influenza vaccine in older adultsNovavax, Inc. reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based v...
Viron Therapeutics' three drug candidates granted U.S. patentsViron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived prote...
HERA trial continues to demonstrate significant patient benefits from HerceptinNew 23-month follow-up data from HERA, one of the largest breast cancer trials ever carried out, sho...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.